Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tiziana Life Sciences ( (TLSA) ) has issued an update.
On May 15, 2025, Tiziana Life Sciences announced the publication of a study in the Journal of Clinical Nuclear Medicine, highlighting the potential of intranasal foralumab in treating moderate Alzheimer’s disease. The study demonstrated a significant reduction in microglial activation in a 78-year-old patient, marking the first use of 18F-PBR06-PET in such a case. This finding suggests a promising new avenue for addressing neuroinflammatory conditions, potentially impacting Tiziana’s market position and offering hope for stakeholders seeking innovative treatments for Alzheimer’s disease.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. The company specializes in immunomodulation therapies, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody. Tiziana’s approach aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods.
Average Trading Volume: 764,314
Technical Sentiment Signal: Buy
Current Market Cap: $180.6M
For a thorough assessment of TLSA stock, go to TipRanks’ Stock Analysis page.